The Filing Desk

Amphstar Pharmaceuticals vs Emergent BioSolutions

Amphstar Pharmaceuticals AMPH · Emergent BioSolutions EBS · Pharmaceuticals

Emergent BioSolutions reported revenue of $743 million in fiscal 2025, about the same as Amphstar Pharmaceuticals' $720 million in fiscal 2025. Amphstar Pharmaceuticals' revenue fell 1.6% in its latest year, and Emergent BioSolutions' fell 28.8%. Amphstar Pharmaceuticals had an operating margin of 19.5%, against 13.5% at Emergent BioSolutions. Free cash flow was $121 million at Amphstar Pharmaceuticals and $157 million at Emergent BioSolutions.

Side by side

Amphstar PharmaceuticalsEmergent BioSolutions
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$720M$743M
Revenue growth−1.6%−28.8%
Revenue growth a year, last 5 years15.5%−14.0%
Gross margin49.5%56.1%
Operating margin19.5%13.5%
Net margin13.6%7.1%
Free cash flow$121M$157M
Free cash flow margin16.8%21.1%
Return on capital9.9%6.4%
Net debt to EBITDA1.7x2.0x
Dividends and buybacks$76M$25M
Change in diluted share count−7.4%7.0%
Last close$28.11$5.15
P/E at the last close12.8×—
Insider trades, last 12 monthssold $2.4 millionsold $840,301
Piotroski F-score6 of 97 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Amphstar PharmaceuticalsEmergent BioSolutions
Operating margin
Percent of revenue
Amphstar PharmaceuticalsEmergent BioSolutions
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Amphstar PharmaceuticalsEmergent BioSolutions

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Amphstar Pharmaceuticals and Emergent BioSolutions pages.